To evaluate the bladder preservation strategy used at our institution for muscle-invasive bladder cancer (MIBC) in patients undergoing chemoradiotherapy.
INTRODUCTION AND OBJECTIVES: Over the last decades, several studies, including our group have shown that the use of trimodal therapy consisting of transurethral bladder resection followed by concomitant chemotherapy and radiation therapy results in comparable outcomes to radical cystectomy, considered the gold standard for muscle invasive bladder cancer (MIBC). We present our oncologic outcomes for tetra-modal bladder preservation technique, which include tri-modal therapy followed by selective intra-arterial infusion of chemotherapeutics.
METHODS: We performed an analysis of our prospectively maintained IRB approved database of multimodal bladder preservation technique. Our tetra-modality therapy consisted of complete resection of the tumor, chemotherapy and radiation therapy followed by dual balloon occluded intra-arterial infusion of chemotherapeutics -OMC regimen. We included all cases from August 2009 until December 2015 with at least 6 months of follow up. We evaluated oncologic outcomes based on T-stage, grade, lymph node status, age, sex, and presence of hydronephrosis. All data was analyzed using SPSS ver15.
RESULTS: Four-hundred ten MIBC patients were enrolled in the study (median age 67 years, 78.8% male, ECOG performance status 0/1/2 100.0%, T-stage II/III/IV 67.1%;23.1%; 9.8%). The mean 8-year OS was 75.1 months (95% CI; 70.5-79.7) for cT II versus 77.1 months (95% CI; 67.7-86.5) for cT III, and 41.8 months (31.7-52.0) for cT IV. Univariate analysis for 8-year OS showed that patients 0 deaths were associated with age (p ¼ 0. , approximately 20% of patients treated with PC have been reported to ultimately require radical cystectomy (RC) for disease recurrence. The outcomes for these patients have not been well described to date. We therefore evaluated perioperative and oncologic outcomes of patients undergoing RC after PC for UC. METHODS: We identified 61 patients who underwent RC at our institution after prior PC for UC between 1980-2010. These patients were then matched 1:3 to patients undergoing primary RC based on age, pathologic T and N stage, and decade of surgery. Perioperative outcomes were compared between the two groups using descriptive statistics. Cancer-specific (CSS) and overall survival (OS) were evaluated using the Kaplan-Meier method and conditional Cox proportional hazards regression models.
RESULTS: Median age at the time of RC was 67 yrs in both groups (IQR 62, 75) , while 47/61 (77%) RC after PC and 151/181 (83.4%) primary RC patients were male. Median time from PC to RC was 1.5 years (IQR 0.6, 4.4) . Median Charlson comorbidity index was 2 for both groups (IQR 2, 8) . Estimated blood loss was significantly higher among patients undergoing RC after PC compared to primary RC (median 1000 cc vs 700 cc; p¼0.001), although there was no difference in operative time (median 322 min vs 292 min; p¼0.17) or length of stay (median 10 vs 11 days; p¼0.27). Similarly, there was no difference in either minor (Clavien 1-2) (49.2% vs 44.8%; p¼0.71) or major (Clavien 3-5) (9.8% vs 8.3%; p¼0.55) perioperative complications between the RC after PC and the RC alone groups. Median follow-up after RC was 6.0 years (IQR 1.5, 15.6), during which time 204 patients died, including Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 THE JOURNAL OF UROLOGY â e249
